Short-Term Efficacy of Triamcinolone Acetonide (Aristocort® C) in Subjects with Atopic Dermatitis

Prior treatment

• Subject has a known or suspected allergy to triamcinolone acetonide (Aristocort® C) or any component of the investigational product.

Other illness

• Subject has clinically infected AD.
• Subject has a history of skin disease or presence of skin condition, other than AD, that would interfere with the study assessments in the opinion of the investigator.
• Subject has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1.
• Subject has any clinically significant medical condition that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.
• Subject has a known history of chronic infectious disease.

Other

• Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
• Subject has a Fitzpatrick's Skin Phototype ≥5.
• Subject is known to have immune deficiency or is immunocompromised.

• Male or female subjects 18 years of age or older at the time of consent.
• Subject has clinically confirmed diagnosis of active AD, according to Hanifin and Rajka criteria.
• Subject has at least a 6-month history of AD and had no significant flares in AD for at least 4 weeks before screening.
• Subject has 2 applications areas (10 X 10 cm) with a lesional surface of at least 6 X 6 cm, preferably located on 2 distinct anatomical areas at Day 1.